慢肺活量下降与肌萎缩侧索硬化呼吸衰竭及死亡相关
本研究基于两项临床试验的893例安慰剂治疗ALS患者及PRO-ACT数据库,回顾分析慢肺活量(SVC)下降速率与呼吸相关临床事件的关系。结果显示SVC平均每月下降2.7个百分点,下降速率较慢者呼吸衰竭、气管切开或死亡风险显著降低。
要点
- SVC平均每月下降2.7个百分点,高龄和低ALSFRS-R评分者下降更快。
- 前6个月SVC下降速率每减慢1.5个百分点/月,后续呼吸事件风险降低19%-23%。
- SVC下降速率是ALS临床进展的重要预后指标。
核心结论
- SVC下降速率与ALS患者呼吸衰竭、气管切开或死亡等临床事件相关,是临床进展的重要指标。
研究设计与样本
- 回顾性研究,纳入2项临床试验(EMPOWER和BENEFIT-ALS)的893例安慰剂治疗ALS患者及PRO-ACT试验数据库。
- EMPOWER试验中456例安慰剂患者用于分析SVC与呼吸相关临床事件的关系。
主要发现
- 893例患者平均年龄56.7岁,基线平均SVC为90.5%,65.5%为男性,20.5%为延髓起病。
- EMPOWER试验中,SVC从基线至1.5年随访平均每月下降2.7个百分点。
临床怎么用
- 监测ALS患者SVC下降速率有助于识别呼吸相关临床事件高风险者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The prognostic value of slow vital capacity (SVC) in relation to respiratory function decline and disease progression in patients with amyotrophic lateral sclerosis (ALS) is not well understood. OBJECTIVE: To investigate the rate of decline in percentage predicted SVC and its association with respiratory-related clinical events and mortality in patients with ALS. DESIGN, SETTING, AND PARTICIPANTS: This retrospective study included 893 placebo-treated patients from 2 large clinical trials (EMPOWER and BENEFIT-ALS, conducted from March 28, 2011, to November 1, 2012, and from October 23, 2012, to March 21, 2014, respectively) and an ALS trial database (PRO-ACT, containing studies completed between 1990 and 2010) to investigate the rate of decline in SVC. Data from the EMPOWER trial (which enrolled adults with possible, probable, or definite ALS; symptom onset within 24 months before screening; and upright SVC at least 65% of predicted value for age, height, and sex) were used to assess the relationship of SVC to respiratory-related clinical events; 456 patients randomized to placebo were used in this analysis. The 2 clinical trials included patients from North America, Australia, and Europe. MAIN OUTCOMES AND MEASURES: Clinical events included the earlier of time to death or time to decline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) respiratory subdomain, time to onset of respiratory insufficiency, time to tracheostomy, and all-cause mortality. RESULTS: Among 893 placebo-treated patients with ALS, the mean (SD) patient age was 56.7 (11.2) years, and the mean (SD) SVC was 90.5% (17.1%) at baseline; 65.5% (585 of 893) were male, and 20.5% (183 of 893) had bulbar-onset ALS. In EMPOWER, average decline of SVC from baseline through 1.5-year follow-up was -2.7 percentage points per month. Steeper declines were found in patients older than 65 years (-3.6 percentage points per month [P = .005 vs <50 years and P = .007 vs 50-65 years) and in patients with an ALSFRS-R total score of 39 or less at baseline (-3.1 percentage points per month [P < .001 vs >39]). When the rate of decline of SVC was slower by 1.5 percentage points per month in the first 6 months, risk reductions for events after 6 months were 19% for decline in the ALSFRS-R respiratory subdomain or death after 6 months, 22% for first onset of respiratory insufficiency or death after 6 months, 23% for first occurrence of tracheostomy or death after 6 months, and 23% for death at any time after 6 months (P < .001 for all). CONCLUSIONS AND RELEVANCE: The rate of decline in SVC is associated with meaningful clinical events in ALS, including respiratory failure, tracheostomy, or death, suggesting that it is an important indicator of clinical progression.
引用
- Andrews JA, Meng L, Kulke SF, et al. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2018. PMID: 29181534. doi:10.1001/jamaneurol.2017.3339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。